Clinical Commander

Back to dossier
cardio.cardiac-tamponade.radiation-induced.v1PRODUCTION
cardio.cardiac-tamponade.radiation-induced.v1

Cardiac tamponade — radiation-induced pericardial disease

cardiologyacuteadult
Hard-required inputs
0 / 8
Care setting:

Encounter flow

9/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Radiation-induced pericardial disease — spectrum from acute pericarditis (weeks) to chronic constriction (years-decades); cardiac MRI + CT essential for differentiating inflammatory vs fibrotic phenotype (ESC 2015 §Radiation-Induced; Lyon EHJ 2022 PMID 35993161)

Inputs
1
Actions
0
Advance rule
Set
Advance when

radiation context confirmed

Patient inputs (10)

Cancer survivors often elderly at presentation; latency median 7-10 years (Aleman JCO 2003)

Compensatory tachycardia in tamponade; less prominent in chronic constriction (ESC 2015)

Radiation specifics: dose, field (mantle vs tangential vs IMRT), mean heart dose, timing (latency 7-10 yr median), prior cancer type, current oncologic status (Darby NEJM 2013 PMID 23484825; Lyon EHJ 2022)

Active malignancy vs remission drives differential (radiation toxicity vs metastatic effusion); current oncologic management may include chemotherapy with cardiotoxic agents (Lyon EHJ 2022)

Renal function for diuretic + drug dosing; KDIGO 2021 race-free eGFR (Inker NEJM 2021)

JVD prominent in both tamponade (Beck triad) and constriction (Kussmaul sign — paradoxical inspiratory rise; ESC 2015)

TTE for effusion size + tamponade physiology + restrictive vs constrictive pattern + tissue Doppler for septal bounce (ESC 2015 Class I; Lyon EHJ 2022)

Hypotension is part of Beck triad in tamponade; preserved BP common in chronic constriction (ESC 2015)

Cardiac MRI for pericardial late gadolinium enhancement + thickening + fibrosis assessment + edema; differentiates inflammatory vs fibrotic component (Lyon EHJ 2022; Heidenreich JACC 2010)

CT for pericardial calcification (highly specific for radiation pericarditis) + thickening + co-existing lung/mediastinal pathology (Lyon EHJ 2022)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationalsevereprogressive_constrictive_pericarditis_with_volume_overload
    Progressive constrictive pericarditis with refractory volume overload (Kussmaul sign, ascites, peripheral edema) in radiation survivor — pericardiectomy mandatory but high-risk in radiation tissue (ESC 2015 §Constrictive; Bertog EHJ 2004)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_effusion_in_radiation_survivor
    Recurrent pericardial effusion despite NSAID + colchicine in radiation survivor — escalate workup (rule out malignancy + effusive-constrictive) + consider pericardial window (ESC 2015; Lyon EHJ 2022)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepericardiectomy_decision_in_radiation_field
    Surgical decision-making for pericardiectomy in radiation-damaged tissue — multidisciplinary balance of refractory symptoms vs operative mortality 10-20% (Bertog EHJ 2004)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecancer_recurrence_vs_radiation_toxicity_attribution
    Cancer recurrence vs radiation toxicity attribution challenge in patient with prior chest radiation presenting with new pericardial effusion — comprehensive workup mandatory (Lyon EHJ 2022)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Radiation-induced pericardial disease — anti-inflammatory for acute pericarditis, drainage for tamponade, pericardiectomy for refractory constriction (ESC 2015 §Radiation-Induced; Lyon EHJ 2022 PMID 35993161; ICAP PMID 23992557)
axis: radiation_induced_pericardial_disease_management
Selected axis "Radiation-induced pericardial disease — anti-inflammatory for acute pericarditis, drainage for tamponade, pericardiectomy for refractory constriction (ESC 2015 §Radiation-Induced; Lyon EHJ 2022 PMID 35993161; ICAP PMID 23992557)" by default fallback (first axis)
  • ibuprofen
    first line
    nsaid_propionic_acid
    600 mg PO TID × 1-2 wk then taper over 2-4 wk • PO • TID
    triggers: acute_pericarditis_with_normal_renal_function
    ESC 2015 Class I + ICAP (Imazio NEJM 2013 PMID 23992557) — first-line anti-inflammatory for acute pericarditis
    rxcui 5640
  • colchicine
    first line
    antimitotic
    0.5 mg BID (0.5 mg daily if <70 kg or eGFR 30-60) × 3 mo • PO • BID
    triggers: acute_pericarditis_recurrent_pericarditis
    ICAP (Imazio NEJM 2013 PMID 23992557) — RR 0.62 for recurrence; CORP (Imazio Ann Intern Med 2011 PMID 21788540) for recurrent
    rxcui 2683
  • acetaminophen
    add on
    analgesic
    650-1000 mg q6h • PO • q6h
    triggers: pain_relief_when_nsaid_contraindicated
    Alternative analgesic when NSAIDs contraindicated (renal impairment, anticoagulation)
    rxcui 161
  • prednisone
    rescue
    corticosteroid
    0.2-0.5 mg/kg PO daily × 2-4 wk then taper • PO • daily
    triggers: nsaid_colchicine_failure_or_contraindication
    ESC 2015 Class IIa second-line for refractory pericarditis; AVOID early in radiation tissue due to wound/healing concern; reserve for refractory cases
    rxcui 8640
  • furosemide
    first line
    loop_diuretic
    20-40 mg IV/PO daily; titrate to euvolemia • IV/PO • daily-BID
    triggers: constrictive_pericarditis_with_volume_overload
    Volume management for constrictive physiology; bridge to definitive surgery (ESC 2015)
    rxcui 4603
  • normal saline
    first line
    isotonic_crystalloid
    500-1000 mL bolus pre-drainage • IV • rapid bolus
    triggers: hypotension_pre_pericardiocentesis
    Bridge preload (ESC 2015)
    rxcui 9863
  • norepinephrine
    rescue
    vasopressor
    0.05-0.1 µg/kg/min titrate MAP ≥65 • IV • continuous
    triggers: SBP_lt_85_despite_fluids_in_tamponade
    Bridge only — does not address obstruction (Roy JAMA 2007)
    rxcui 7512
  • rilonacept
    rescue
    il1_trap
    320 mg SC loading then 160 mg SC weekly • SC • weekly
    triggers: recurrent_pericarditis_failing_nsaid_colchicine_steroids
    RHAPSODY (Klein NEJM 2021 PMID 33999548) — IL-1 blockade for recurrent pericarditis; consider for radiation-related recurrent pericarditis
    rxcui 763450

outpatient playbook — drug actions (3)

  1. 1. as needed treatment for recurrent pericarditis
    rxcui 5640
    ibuprofen 600 mg TID + colchicine 0.5 mg BID for 3 mo for recurrence • PO • TID + BID
    trigger: Recurrent pericarditis episode
    CORP (Imazio Ann Intern Med 2011 PMID 21788540) + ICAP
  2. 2. rilonacept for recurrent refractory
    rxcui 966571
    160 mg SC weekly maintenance after 320 mg load • SC • weekly
    trigger: Multiple recurrences failing NSAID + colchicine ± steroids
    RHAPSODY PMID 33999548
  3. 3. CV risk modification per radiation-induced CAD risk
    rxcui 83367
    atorvastatin 40 mg daily if LDL elevated or radiation-induced CAD • PO • daily
    trigger: Elevated CV risk in radiation survivor
    AHA 2022 cardio-oncology + ASCVD prevention

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Cancer survivor (Hodgkin lymphoma, breast, lung, esophageal) with chest radiation history >30 Gy or mean heart dose >5 Gy presenting with dyspnea, edema, fatigue (ESC 2015 §Radiation-Induced; Lyon EHJ 2022 PMID 35993161); Echo with pericardial thickening or new effusion in radiation survivor (ESC 2015); Acute pericarditis within weeks of completing radiation course (less common with modern conformal techniques) (Heidenreich JACC 2010).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — radiation-induced pericardial disease** (cardio.cardiac-tamponade.radiation-induced.v1).
Phenotype framing: Differentiate: pure radiation toxicity (LGE pattern + thickening + calcification + remission) vs metastatic recurrence (mass + cytology + tumor markers; route to cardio.cardiac-tamponade.malignant.v1) vs effusive-constrictive pericarditis vs concurrent cardiotoxic chemo (anthracycline cardiomyopathy with secondary effusion); cancer survivorship requires comprehensive workup (Lyon EHJ 2022)
Scope: Radiation-induced pericardial disease — spectrum from acute pericarditis (weeks) to chronic constriction (years-decades); cardiac MRI + CT essential for differentiating inflammatory vs fibrotic phenotype (ESC 2015 §Radiation-Induced; Lyon EHJ 2022 PMID 35993161)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Radiation-induced pericardial disease — anti-inflammatory for acute pericarditis, drainage for tamponade, pericardiectomy for refractory constriction (ESC 2015 §Radiation-Induced; Lyon EHJ 2022 PMID 35993161; ICAP PMID 23992557)**.
1. ibuprofen 600 mg PO TID × 1-2 wk then taper over 2-4 wk PO TID (nsaid_propionic_acid, first line) — ESC 2015 Class I + ICAP (Imazio NEJM 2013 PMID 23992557) — first-line anti-inflammatory for acute pericarditis
2. colchicine 0.5 mg BID (0.5 mg daily if <70 kg or eGFR 30-60) × 3 mo PO BID (antimitotic, first line) — ICAP (Imazio NEJM 2013 PMID 23992557) — RR 0.62 for recurrence; CORP (Imazio Ann Intern Med 2011 PMID 21788540) for recurrent
3. acetaminophen 650-1000 mg q6h PO q6h (analgesic, add on) — Alternative analgesic when NSAIDs contraindicated (renal impairment, anticoagulation)
4. prednisone 0.2-0.5 mg/kg PO daily × 2-4 wk then taper PO daily (corticosteroid, rescue) — ESC 2015 Class IIa second-line for refractory pericarditis; AVOID early in radiation tissue due to wound/healing concern; reserve for refractory cases
5. furosemide 20-40 mg IV/PO daily; titrate to euvolemia IV/PO daily-BID (loop_diuretic, first line) — Volume management for constrictive physiology; bridge to definitive surgery (ESC 2015)
6. normal saline 500-1000 mL bolus pre-drainage IV rapid bolus (isotonic_crystalloid, first line) — Bridge preload (ESC 2015)
7. norepinephrine 0.05-0.1 µg/kg/min titrate MAP ≥65 IV continuous (vasopressor, rescue) — Bridge only — does not address obstruction (Roy JAMA 2007)
8. rilonacept 320 mg SC loading then 160 mg SC weekly SC weekly (il1_trap, rescue) — RHAPSODY (Klein NEJM 2021 PMID 33999548) — IL-1 blockade for recurrent pericarditis; consider for radiation-related recurrent pericarditis

Setting playbook (outpatient) — Long-term cancer survivorship cardiac surveillance (annual echo + symptom assessment + comprehensive cardiac MRI q3-5 yr in high-risk cohorts); recurrence prevention; pericardiectomy follow-up if performed (Lyon EHJ 2022 PMID 35993161; Heidenreich JACC 2010)
9. as needed treatment for recurrent pericarditis ibuprofen 600 mg TID + colchicine 0.5 mg BID for 3 mo for recurrence PO TID + BID — Recurrent pericarditis episode (CORP (Imazio Ann Intern Med 2011 PMID 21788540) + ICAP)
10. rilonacept for recurrent refractory 160 mg SC weekly maintenance after 320 mg load SC weekly — Multiple recurrences failing NSAID + colchicine ± steroids (RHAPSODY PMID 33999548)
11. CV risk modification per radiation-induced CAD risk atorvastatin 40 mg daily if LDL elevated or radiation-induced CAD PO daily — Elevated CV risk in radiation survivor (AHA 2022 cardio-oncology + ASCVD prevention)

Non-pharmacologic actions:
- Cardiology annual or biennial follow-up
- Oncology surveillance per cancer protocol
- Cardiothoracic surgery follow-up post-pericardiectomy
- Cardiac rehabilitation if appropriate post-pericardiectomy
- Smoking cessation, BP control, lipid management for compounded CV risk

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain (ESC 2015)
- Nsaid_AVOID_eGFR_lt_30_or_active_GI_bleed_or_anticoagulation_high_bleed (ESC 2015)
- Corticosteroids_AVOID_early_in_radiation_tissue_wound_healing_concern_reserve_for_refractory (ESC 2015 §Radiation Induced)
- Pericardiectomy_high_operative_mortality_10 20%_in_radiation_damaged_tissue (Bertog EHJ 2004)
- Colchicine_dose_reduce_renal_impairment_egfr_30 60 (drug label)
- Colchicine_AVOID_severe_renal_impairment_egfr_lt_30_concurrent_strong_cyp3a4_clarithromycin (drug label)

Monitoring

Regimen monitoring:
- echo during active treatment q2-4wk then q3mo (ESC 2015)
- long term cardiac surveillance in radiation survivors annual echo per lyon 2022 (Lyon EHJ 2022 PMID 35993161)
- comprehensive cardiac MRI q3-5yr in high risk cohorts mantle radiation mean heart dose gt 15 gy (Lyon 2022)
- CRP + ESR to track inflammatory response (ESC 2015)
- CBC renal function during NSAID + colchicine treatment
- symptom assessment dyspnea edema fatigue chest pain at each visit
- oncology co management with cardiology (Lyon 2022)

Setting (outpatient) monitoring:
- Annual echo
- Cardiac MRI q3-5 yr in high-risk cohorts (Lyon 2022)
- Annual lipid + HbA1c
- ECG annually

Monitoring phase: Re-accumulation surveillance (echo q12-24h initial then per clinical course); long-term cancer-survivorship surveillance per Lyon 2022 (annual echo + symptom assessment + comprehensive cardiac MRI q3-5 yr for high-risk cohorts: mantle radiation, mean heart dose >15 Gy)

Disposition

Current setting: outpatient — Long-term cancer survivorship cardiac surveillance (annual echo + symptom assessment + comprehensive cardiac MRI q3-5 yr in high-risk cohorts); recurrence prevention; pericardiectomy follow-up if performed (Lyon EHJ 2022 PMID 35993161; Heidenreich JACC 2010)

Disposition criteria:
- Stable + survivorship surveillance ongoing + no acute decompensation → routine annual cardiology follow-up

Escalation triggers (move to higher acuity):
- Recurrent pericarditis → NSAID + colchicine taper + escalate to rilonacept if failing
- Constrictive deterioration → cardiothoracic surgery for pericardiectomy reassessment
- New cancer recurrence → multidisciplinary reassessment
- Late radiation cardiotoxicity (CAD, valvular disease, cardiomyopathy) → cardiology workup
- Tamponade recurrence → re-route to acute pathway

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] Progressive constrictive pericarditis with refractory volume overload (Kussmaul sign, ascites, peripheral edema) in radiation survivor — pericardiectomy mandatory but high-risk in radiation tissue (ESC 2015 §Constrictive; Bertog EHJ 2004)
- [SEVERE] Recurrent pericardial effusion despite NSAID + colchicine in radiation survivor — escalate workup (rule out malignancy + effusive-constrictive) + consider pericardial window (ESC 2015; Lyon EHJ 2022)
- [SEVERE] Surgical decision-making for pericardiectomy in radiation-damaged tissue — multidisciplinary balance of refractory symptoms vs operative mortality 10-20% (Bertog EHJ 2004)

Citations

- 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Radiation-Induced Pericarditis remains current as of 2026-05-15; 2022 ESC Cardio-oncology Guideline (Lyon EHJ 2022 PMID 35993161) anchors cancer survivorship surveillance + pericardial disease management in oncology context. Heidenreich JACC 2010 (radiation cardiotoxicity comprehensive review), Darby NEJM 2013 PMID 23484825 (mean heart dose threshold breast cancer), Bertog EHJ 2004 (pericardiectomy outcomes in radiation), Hancock JAMA 1993 (Hodgkin lymphoma cardiac mortality), and Aleman JCO 2003 (late mortality Hodgkin survivors) anchor radiation-specific epidemiology + pathophysiology + surgical risk. [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 35993161) [PMID:35993161](https://pubmed.ncbi.nlm.nih.gov/35993161/)
- Cited evidence (PMID 23484825) [PMID:23484825](https://pubmed.ncbi.nlm.nih.gov/23484825/)
- Cited evidence (PMID 17456823) [PMID:17456823](https://pubmed.ncbi.nlm.nih.gov/17456823/)
- Cited evidence (PMID 23992557) [PMID:23992557](https://pubmed.ncbi.nlm.nih.gov/23992557/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Radiation-Induced Pericarditis remains current as of 2026-05-15; 2022 ESC Cardio-oncology Guideline (Lyon EHJ 2022 PMID 35993161) anchors cancer survivorship surveillance + pericardial disease management in oncology context. Heidenreich JACC 2010 (radiation cardiotoxicity comprehensive review), Darby NEJM 2013 PMID 23484825 (mean heart dose threshold breast cancer), Bertog EHJ 2004 (pericardiectomy outcomes in radiation), Hancock JAMA 1993 (Hodgkin lymphoma cardiac mortality), and Aleman JCO 2003 (late mortality Hodgkin survivors) anchor radiation-specific epidemiology + pathophysiology + surgical risk. — PMID:26320112
  • Cited evidence (PMID 35993161) — PMID:35993161
  • Cited evidence (PMID 23484825) — PMID:23484825
  • Cited evidence (PMID 17456823) — PMID:17456823
  • Cited evidence (PMID 23992557) — PMID:23992557